10:08 AM EDT, 06/03/2024 (MT Newswires) -- Genmab ( GMAB ) said Monday that its antibody-drug conjugate tisotumab vedotin showed "encouraging" antitumor activity as a monotherapy in a phase 2 trial in patients with head and neck squamous cell carcinoma which progressed on or after first-line treatment.

Citing phase 2 data, the company said 32.5% of patients achieved a confirmed objective response rate, one patient had a complete response and 12 showed a partial response.

No new safety signals were observed in the study, Genmab ( GMAB ) said.

Tisotumab vedotin is approved by the US Food and Drug Administration as a treatment for recurrent or metastatic cervical cancer, the company said.

Price: 28.45, Change: +0.25, Percent Change: +0.89